Viking Therapeutics Inc

VKTX is in a structural repair phase marked by a Bearish Pivot Point and sits oversold, making it eligible for mean-reversion counter-trend entries. Medium-term permission is bullish under oversold conditions, and short-term timing supports immediate participation as price approaches key support zones.

• ↑Viking’s $502M cash reserve funds R&D through 2028, sustaining clinical development of VK2735.
• ↑Full enrollment in Phase 3 VANQUISH trials paves way for topline data readout and potential FDA submission.
• ↓Net loss surged to $128M in Q2 2026 from $65.6M a year earlier, straining cash burn profile.